+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Painful Diabetic Neuropathy Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • PDF Icon

    Report

  • 131 Pages
  • July 2022
  • Region: Global
  • Acute Market Reports
  • ID: 5641378

The Painful Diabetic Neuropathy Drugs Market is forecasted to grow at a CAGR of 7% during the forecast period of 2022 to 2030. Painful diabetic peripheral neuropathy occurs in approximately 25% of patients with diabetes mellitus who have treated in the office sitting & sedentary lifestyle. It typically causes burning pain, paresthesia & numbness in a stocking-glove pattern that progress from the feet & hands. Healthcare should carefully consider the patient's goal, functional status & potential adverse effects of medication when choosing a treatment for painful diabetic peripheral neuropathy. Pregabalin and duloxetine are the two types of medications approved by the U.S. Food and Drug Administration for treating this disorder.

Peripheral Treatment trends the market

The treatment includes several medications such as, Anticonvulsants, Tricyclic antidepressants, Serotonin-norepinephrine reuptake inhibitors, Opioid-like medications, Topical medications, Selective serotonin reuptake inhibitors & Opioids. The medicines inhaled in this treatment costs about a range of 8$ - 560$. They also have adverse effect as, nausea, headache, dizziness, peripheral edema, weight gain, constipation, Diarrhea, anxiety, vomiting, somnolence, insomnia & so on. The range of patients causing adverse effect may vary from 5 % to 60 %. Various treatments for Painful Diabetic Neuropathy but the most effective & efficient is the peripheral treatment.

Increasing Prevalence Remains the Key Impeder

Diabetes has become one of the largest global health care diseases of the 21 st century. According to the Centers for Disease Control and Prevention CDCP, the population prevalence of diabetes in the North America is approaching 10% and is increasing by 5% each year. The number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. Spread of diabetes has been emerging more rapidly in low & middle income countries than in high income countries. Approximately, 60 million people in the European Region are living with this disease, by straining the Region’s economies and health systems. Prevalence of diabetes is increasing in the European Region has reached 10-12% of the population in some of the States. This increase is strongly associated with increasing trends towards overweight and obesity, unhealthy diets, physical inactivity and socioeconomic disadvantage. This trend is significantly increasing the prevalence of diabetic Neuropathy as well.

Market Key Players

Some of the key players include Daiichi Sankyo Company, Eli Lilly and Company, Johnson & Johnson Services, Novartis AG, Pfizer Inc, Grunenthal GmbH, ViroMed Co, Collegium Pharmaceutical, Acorda Therapeutics, Zydus Pharmaceuticals, Mallinckrodt, Macleods Pharmaceuticals Ltd, Lupin Pharmaceuticals.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. Key data points that enables the estimation of Painful Diabetic Neuropathy Drugs market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Painful Diabetic Neuropathy Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key Questions Answered in This Report

  • What are the key micro and macro environmental factors that are impacting the growth of Painful Diabetic Neuropathy Drugs market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Painful Diabetic Neuropathy Drugs market?
  • Which is the largest regional market for Painful Diabetic Neuropathy Drugs market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Painful Diabetic Neuropathy Drugs market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Painful Diabetic Neuropathy Drugs market worldwide?

Table of Contents

1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Painful Diabetic Neuropathy Drugs Market
2.2. Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021 (US$ Million)
2.3. Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021 (US$ Million)
2.4. Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021 (US$ Million)
2.5. Global Painful Diabetic Neuropathy Drugs Market, By Geography, 2021 (US$ Million)
2.6. Global Painful Diabetic Neuropathy Drugs Market, By Impact of COVID-19, 2020 (US$ Million)
2.7. Key Investment Proposition by Geography, 2021
2.8. Competitive Analysis
2.9. Key Industry Strategies
2.10. Tier Analysis 2021 Versus 2030
2.11. Key Buying Criteria
2.12. Key Case Reports
2.13. Scenario Analysis
2.14. Optimistic estimates and analysis
2.15. Realistic estimates and analysis
2.16. Pessimistic estimates and analysis
2.17. Market Profiling
2.18. Sales and Marketing Plan
2.19. Heptalysis Analysis
2.20. Critical Investigation of Business Problems Through Five Whys Root Cause Analysis & Relevant Solutions
2.21. Top Market Conclusions
2.22. Strategic Recommendations
3. Painful Diabetic Neuropathy Drugs Market: Business Outlook & Market Dynamics
3.1. Introduction
3.2. Global Painful Diabetic Neuropathy Drugs Market Value, 2020 - 2030, (US$ Million)
3.3. Key Trends Analysis
3.4. Market Dynamics
3.4.1. Market Drivers
3.4.2. Market Restraints
3.4.3. Key Challenges
3.4.4. Key Opportunities
3.5. Impact Analysis of Drivers and Restraints
3.6. See-Saw Analysis
3.7. Attractive Investment Proposition
3.8. Porter’s Five Force Model
3.8.1. Supplier Power
3.8.2. Buyer Power
3.8.3. Threat Of Substitutes
3.8.4. Threat Of New Entrants
3.8.5. Competitive Rivalry
3.9. PESTEL Analysis
3.9.1. Political Landscape
3.9.2. Economic Landscape
3.9.3. Technology Landscape
3.9.4. Legal Landscape
3.9.5. Social Landscape
3.10. Competitive Landscape
3.10.1. Market Positioning of Key Painful Diabetic Neuropathy Drugs Market Vendors
3.10.2. Strategies Adopted by Painful Diabetic Neuropathy Drugs Market Vendors
4. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
4.1. Market Overview
4.2. Growth & Revenue Analysis: 2021 Versus 2030
4.3. Market Segmentation
4.3.1. Anticonvulsants
4.3.2. Tricyclic antidepressants
4.3.3. Serotonin-norepinephrine reuptake inhibitors
4.3.4. Opioid
4.3.5. Topical medications
4.3.6. Selective serotonin reuptake inhibitors
5. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Peripheral
5.3.2. Focal
5.3.3. Proximal
5.3.4. Autonomic
6. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
6.3.1. Online Pharmaceuticals
6.3.2. Retail Pharmacy stores
6.3.3. Hospitals
7. North America Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
7.5.1.North America
7.5.1.1. U.S.
7.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.1.2. Canada
7.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
7.5.1.3. Rest of North America
7.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
7.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
7.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8. UK and European Union Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
8.5.1.UK and European Union
8.5.1.1. UK
8.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.2. Germany
8.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.3. Spain
8.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.4. Italy
8.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.5. France
8.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
8.5.1.6. Rest of Europe
8.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
8.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
8.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9. Asia Pacific Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
9.5.1.Asia Pacific
9.5.1.1. China
9.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.2. Japan
9.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.3. India
9.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.4. Australia
9.5.1.4.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.4.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.4.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.5. South Korea
9.5.1.5.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.5.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.5.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
9.5.1.6. Rest of Asia Pacific
9.5.1.6.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
9.5.1.6.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
9.5.1.6.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10. Latin America Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
10.5.1.Latin America
10.5.1.1. Brazil
10.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.1.2. Mexico
10.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
10.5.1.3. Rest of Latin America
10.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
10.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
10.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11. Middle East and Africa Painful Diabetic Neuropathy Drugs Market, 2020-2030, USD (Million)
11.1. Market Overview
11.2. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.3. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.4. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.Painful Diabetic Neuropathy Drugs Market: By Region, 2020-2030, USD (Million)
11.5.1.Middle East and Africa
11.5.1.1. GCC
11.5.1.1.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.1.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.1.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.1.2. Africa
11.5.1.2.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.2.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.2.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
11.5.1.3. Rest of Middle East and Africa
11.5.1.3.1. Painful Diabetic Neuropathy Drugs Market: By Drug Type, 2020-2030, USD (Million)
11.5.1.3.2. Painful Diabetic Neuropathy Drugs Market: By Disease, 2020-2030, USD (Million)
11.5.1.3.3. Painful Diabetic Neuropathy Drugs Market: By Application area, 2020-2030, USD (Million)
12. Company Profile
12.1. Daiichi Sankyo Company, Limited
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Eli Lilly and Company
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Johnson & Johnson Services, Inc
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Novartis AG
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Pfizer Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Grunenthal GmbH
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. ViroMed Co.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Collegium Pharmaceutical, Inc
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Acorda Therapeutics, Inc
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Zydus Pharmaceuticals
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Mallinckrodt, Inc
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Macleods Pharmaceuticals Ltd.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives
12.13. Lupin Pharmaceuticals
12.13.1. Company Overview
12.13.2. Financial Performance
12.13.3. Product Portfolio
12.13.4. Strategic Initiatives

List of Figures
FIG. 1 Global Painful Diabetic Neuropathy Drugs Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Painful Diabetic Neuropathy Drugs Market: Quality Assurance
FIG. 5 Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021
FIG. 6 Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021
FIG. 7 Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021
FIG. 8 Global Painful Diabetic Neuropathy Drugs Market, By Geography, 2021
FIG. 9 Market Geographical Opportunity Matrix - Global Painful Diabetic Neuropathy Drugs Market, 2021
FIG. 10 Market Positioning of Key Painful Diabetic Neuropathy Drugs Market Players, 2021
FIG. 11 Global Painful Diabetic Neuropathy Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
FIG. 12 Porters Five Force Model - Current, Midterm and Long Term Perspective
FIG. 13 See Saw Analysis
FIG. 14 PETEL Analysis
FIG. 15 Key Buying Criteria: Current and Long-Term Perspective
FIG. 16 Global Painful Diabetic Neuropathy Drugs Market, Scenario Analysis, 2020 to 2030 (US$ Million)
FIG. 17 Heptalysis Analysis: Global Painful Diabetic Neuropathy Drugs Market
FIG. 18 Five Whys Analysis
FIG. 19 Global Painful Diabetic Neuropathy Drugs Market, By Drug Type, 2021 Vs 2030, %
FIG. 20 Global Painful Diabetic Neuropathy Drugs Market, By Disease, 2021 Vs 2030, %
FIG. 21 Global Painful Diabetic Neuropathy Drugs Market, By Application area, 2021 Vs 2030, %
FIG. 22 U.S. Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 23 Canada Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 24 Rest of North America Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 25 UK Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 26 Germany Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 27 Spain Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 28 Italy Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 29 France Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 30 Rest of Europe Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 31 China Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 32 Japan Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 33 India Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 34 Australia Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 35 South Korea Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 36 Rest of Asia Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 37 Brazil Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 38 Mexico Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 39 Rest of Latin America Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 40 GCC Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 41 Africa Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030
FIG. 42 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market (US$ Million), 2020 - 2030

List of Tables
TABLE 1 Global Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 2 Global Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 3 Global Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 4 North America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 5 North America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 6 North America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 7 U.S. Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 8 U.S. Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 9 U.S. Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 10 Canada Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 11 Canada Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 12 Canada Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 13 Rest of North America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 14 Rest of North America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 15 Rest of North America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 16 UK and European Union Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 17 UK and European Union Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 18 UK and European Union Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 19 UK Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 20 UK Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 21 UK Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 22 Germany Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 23 Germany Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 24 Germany Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 25 Spain Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 26 Spain Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 27 Spain Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 28 Italy Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 29 Italy Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 30 Italy Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 31 France Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 32 France Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 33 France Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 34 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 35 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 36 Rest of Europe Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 37 Asia Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 38 Asia Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 39 Asia Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 40 China Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 41 China Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 42 China Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 43 Japan Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 44 Japan Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 45 Japan Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 46 India Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 47 India Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 48 India Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 49 Australia Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 50 Australia Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 51 Australia Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 52 South Korea Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 53 South Korea Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 54 South Korea Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 55 Latin America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 56 Latin America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 57 Latin America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 58 Brazil Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 59 Brazil Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 60 Brazil Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 61 Mexico Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 62 Mexico Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 63 Mexico Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 64 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 65 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 66 Rest of Latin America Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 67 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 68 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 69 Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 70 GCC Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 71 GCC Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 72 GCC Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 73 Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 74 Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 75 Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)
TABLE 76 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Drug Type, 2020-2030, USD (Million)
TABLE 77 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Disease, 2020-2030, USD (Million)
TABLE 78 Rest of Middle East and Africa Painful Diabetic Neuropathy Drugs Market By Application area, 2020-2030, USD (Million)

Companies Mentioned

  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Pfizer Inc.
  • Grunenthal GmbH
  • ViroMed Co.
  • Collegium Pharmaceutical Inc.
  • Acorda Therapeutics Inc.
  • Zydus Pharmaceuticals
  • Mallinckrodt Inc.
  • Macleods Pharmaceuticals Ltd.
  • Lupin Pharmaceuticals